Ignite Creation Date:
2024-05-05 @ 11:54 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00173745
Status:
UNKNOWN
Last Update Posted:
2005-12-21
First Post:
2005-09-12
Brief Title:
Treatment of Drooling With Type A Botulinum Toxin in Children With Cerebral Palsy
Sponsor:
National Taiwan University Hospital
Organization:
National Taiwan University Hospital
Study Overview
Official Title:
Treatment of Drooling With Type A Botulinum Toxin A in Children With Cerebral Palsy
Status:
UNKNOWN
Status Verified Date:
2002-07
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the effectiveness of botulinum toxin injection to treat drooling in children with cerebral palsy and to find the most appropriate dosage duration of effect and side effects
Detailed Description:
Sialorrhea or drooling has been reported to be a significant problem in 10to 37 of patients with cerebral palsy Excessive drooling may cause skin maceration increased the burden of caregiver affect articulation of the patients and increase the risk of aspiration and dehydration Many options including various therapies medications surgeries and radiation have been proposed to treat drooling Yet none of these is universally successful and many have potential complications Nerve endings of the parasympathetic post-ganglionic neurons secret aceylcholine Botulinum toxin should be able to inhibit salivary gland secretion by blocking the release of acetylcholine Very limited case series had proved fair result of botulinum toxin injection to treat drooling However most of the subjects were adult patients with neurological disorders The purpose of this study is to evaluate the effectiveness of botulinum toxin injection to treat drooling in children with cerebral palsy and to find the most appropriate dosage duration of effect and side effects
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NSC93-2614-B-002-005 | None | None | None |